Human lenses were obtained from eyes donated for corneal transplantation to Mid America Transplant Services. The use of human lenses was approved by the Washington University Institutional Review Board and conformed to the Declaration of Helsinki. All experiments using animals conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Washington University Animal Studies Committee. Adult mice and rats were killed by CO2 inhalation and rabbits by overdose of pentobarbital. Eyes were removed immediately and either fixed or kept on ice. Lenses were removed and epithelia and fibers separated by dissection. To decrease oxygen levels in the anterior chamber, mice or rabbits were anesthetized with ketamine (30 mg/kg) and medetomine (1 mg/kg; for mice) or xylazine (5 mg/kg; for rabbits), and one eyelid from each animal was closed with 6-0 (rabbits) or 7-0 (mice) silk sutures for 3 days. Care was taken that the sutures did not penetrate the inner surface of the lid where they might irritate the corneal epithelium.
For immunocytochemistry, mouse embryos and adult eyes were fixed in 10% neutral buffered formalin and tissue sections prepared after embedding in paraffin. Sections pretreated by boiling for 15 minutes in 0.01 M citrate buffer (pH 6.0) and stained with a 1:500 dilution of polyclonal rabbit anti-VEGF-A antibody (SC-507; Santa Cruz Biotechnology, Santa Cruz, CA) or a 1:2000 dilution of rabbit anti-VEGFR2 (SC-315; Flk-1; Santa Cruz Biotechnology). Control experiments were performed by omitting the primary antibody or by pretreating the VEGF-A antibody with a 10-fold excess (by weight) of human VEGF-A (R&D Systems, Minneapolis, MN) or a 5-fold excess of the peptide against which the VEGFR2 antibody had been generated (SC-315p; Santa Cruz Biotechnology).
Western blot analysis was performed by standard methods, and bands were visualized using chemiluminescence. Each experiment was performed a minimum of three times. Tissues were prepared in radioimmunoprecipitation assay (RIPA) buffer containing a protease inhibitor cocktail at the recommended concentration (Complete; Roche Diagnostics, Indianapolis, IN) and 0.2 mg/mL sodium orthovanadate. Protein concentration was measured using a reagent (D C Protein Assay Reagent; Bio-Rad Laboratories, Hercules, CA) in microtiter plates with bovine serum albumin as a standard. Each blot was stained with ponceau S to confirm that equal amounts of total protein were loaded. The specificity of the blots was determined by adding a 10-fold excess (by weight) of human VEGF-A or a 5-fold excess of the immunizing peptide for VEGFR2 (SC-315p; Santa Cruz Biotechnology) to the diluted antibody and incubating at 4°C overnight before adding the mixture to the blot. In some experiments, antigens were first immunoprecipitated with one primary antibody and the immunoprecipitated proteins Western blotted with a second antibody. For VEGF-A, five whole adult mouse lenses were incubated in 1 mL of lysis buffer for 1 hour at 4°C and the lysate centrifuged for 5 minutes at approximately 2000g. Mouse anti-VEGF-A monoclonal antibody (12 μL SC-7269) was added to 100 μL of the supernatant and incubated at 4°C for 2 hours, and 30 μL of protein A/G beads (SC-2003; Santa Cruz Biotechnology) were then added and incubated overnight in a cold room with gentle rocking. The beads were pelleted by gentle centrifugation, the supernatant discarded, and the beads washed once with PBS, resuspended in 15 μL of electrophoresis loading buffer, and heated at 80°C for 3 minutes before electrophoresis. The blot was probed overnight at 4°C or for 2 hours at room temperature with anti-VEGF-A rabbit polyclonal antibody (SC-507; Santa Cruz Biotechnology) at a dilution of 1:1,000 and the bound antibody detected with anti-rabbit secondary antibody conjugated to horseradish peroxidase at a dilution of 1:10,000 (SC-2030; Santa Cruz Biotechnology). A similar procedure was used to detect VEGFR2 (Flk-1) extracted from adult mouse lenses, except that the mouse monoclonal antibody used for immunoprecipitation was SC-6251, and the rabbit polyclonal antibody used for blotting was SC-315 (both from Santa Cruz Biotechnology) at a dilution of 1:500. Tyrosine phosphorylated VEGFR2 was immunoprecipitated by using agarose beads coupled to monoclonal anti-phosphotyrosine (SC-707; Santa Cruz Biotechnology), the bound material was dissolved in electrophoresis sample buffer, and the blot probed with anti-VEGFR2 (SC-315; Santa Cruz Biotechnology).
VEGF-A mRNA levels were measured and compared with β-actin mRNA levels in mouse lenses at postnatal day 5 (P5), P10, P12, P16 and in adults using
TaqMan probes (Applied Biosystems, Inc., Foster City, CA) to perform quantitative PCR. PCR primers were designed to amplify mouse β-actin, total mouse VEGF-A, and each of the three isoforms of mouse VEGF-A (VEGF-A
120, -A
164, and -A
188). The PCR primers and probe sequences are listed in
Table 1 . The single
TaqMan probe detected total VEGF-A mRNA and each of the isoforms of VEGF-A, depending on the primer pairs used. Total RNA was extracted with an RNA isolation reagent (RNAwiz; Ambion, Austin, TX) and treated with DNase (DNA-free; Ambion) to remove any contaminating genomic DNA, and 1 μg was reverse transcribed (RetroScript reverse transcriptase; Ambion) in a total volume of 20 μL according to the instructions provided by the manufacturer. For each 50-μL PCR reaction, 0.6 μL of the reverse transcription product was amplified in a thermal cycler (iCycler; Bio-Rad), using the
TaqMan probe at a final concentration of 0.2 μM in a standard PCR mixture with
Taq polymerase (Ampli
Taq Gold; Applied Biosystems, Inc.). PCR efficiency was determined using serial dilution of a known concentration of a plasmid containing the β-actin sequence. Each sample was run in triplicate, and each experiment was performed at least twice.